Disparities in the practice of precision medicine? Using multi-gene testing in early-stage, HR+/HER2-breast cancer

被引：0
|
作者：
Bilani, Nadeem
Yaghi, Marita
Saravia, Diana
Jabbal, Iktej
Zerdan, Maroun Bou
Elson, Leah
Hong, Liang
Nahleh, Zeina
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P1-08-33
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-08-33
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Composite score combining multi-gene testing with liquid biopsy may have stronger prognostic value in HR+/HER2-breast cancer
    Bilani, Nadeem
    Yaghi, Marita
    Saravia, Diana
    Jabbal, Iktej
    Zerdan, Maroun Bou
    Elson, Leah
    Liang, Hong
    Nahleh, Zeina
    CANCER RESEARCH, 2022, 82 (04)
  • [2] UNDERSTANDING THE HUMANISTIC AND ECONOMIC BURDEN ASSOCIATED WITH EARLY-STAGE HR+/HER2-BREAST CANCER: A SYSTEMATIC LITERATURE REVIEW
    Earla, J. R.
    Singh, P.
    Bozkaya, D.
    Nathani, J.
    Pandey, P.
    Haiderali, A.
    VALUE IN HEALTH, 2024, 27 (06) : S64 - S65
  • [3] Predictive score for response to neoadjuvant chemotherapy in early-stage HR + /HER2-breast cancer
    Coelho, Joao Queiros
    Lau, Beatriz
    Pichel, Rita
    Guerra, Laura
    Miranda, Hugo
    Romao, Raquel
    Sousa, Maria Joao
    Goncalves, Fernando
    Simoes, Joana
    Azevedo, Sergio Xavier
    Araujo, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [4] SG Improves OS in HR+/HER2-Breast Cancer
    Poh, Alissa
    CANCER DISCOVERY, 2022, 12 (12) : 2714 - 2715
  • [5] Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2-Breast Cancer
    Bottosso, Michele
    Miglietta, Federica
    Vernaci, Grazia Maria
    Giarratano, Tommaso
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Griguolo, Gaia
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2884 - 2894
  • [6] Controversies on chemotherapy for early HR+/HER2-breast cancer: the role of anthracyclines and dose intensification
    Poggio, Francesca
    Molinelli, Chiara
    Giannubilo, Irene
    Lambertini, Matteo
    Blondeaux, Eva
    CURRENT OPINION IN ONCOLOGY, 2024, 36 (06) : 495 - 502
  • [7] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2-Breast Cancer
    Kang, Connie
    TARGETED ONCOLOGY, 2024, 19 (02) : 289 - 296
  • [8] Impact of molecular subtype and race on HR+, HER2-breast cancer survival
    Reid, Sonya
    Haddad, Diane
    Tezak, Ann
    Weidner, Anne
    Wang, Xuefeng
    Mautz, Brian
    Moore, Jaleesa
    Cadiz, Sydney
    Zhu, Yuwei
    Zheng, Wei
    Mayer, Ingrid A.
    Shu, Xiao-ou
    Pal, Tuya
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 845 - 852
  • [9] Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
    Prat, A.
    Falato, C.
    Pare Brunet, L.
    Martinez Saez, O.
    Cejalvo Andujar, J. M.
    Margeli Vila, M.
    Tolosa, P.
    Salvador Bofill, F. J.
    Cruz Jurado, J.
    Gonzalez-Farre, B.
    Sanfeliu Torres, E.
    Ciruelos, E. M.
    Espinosa-Bravo, M.
    Izarzugaza Peron, Y.
    Pernas Simon, S.
    Esker, S.
    Fan, P-D.
    Ferrero Cafiero, J. M.
    Pascual, T.
    Oliveira, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S164 - S164
  • [10] Tumour stroma characterization for the clinical stratification of HR+/HER2-breast cancer
    Scatena, C.
    Fanelli, G. N.
    Belcastro, E.
    Di Cocco, F.
    Fontana, A.
    Szumera-Cieckiewicz, A.
    Loda, M.
    Naccarato, A. G.
    VIRCHOWS ARCHIV, 2024, 485 : S5 - S5
12345